Deborah Dodge

Deborah Dodge is an accomplished scientific professional with extensive experience in cell biology and drug discovery, currently serving in the Discovery Technology role at Sail Biomedicines since April 2022. Previous positions include contributions to the Brain Targeting Program at the Wyss Institute for Biologically Inspired Engineering and senior scientist roles at Cyclerion, Ironwood Pharmaceuticals, and Ensemble Therapeutics, where key projects encompassed oncology programs and metabolic disease. With a research background in inflammation at Resolvyx Pharmaceuticals and assay development at Critical Therapeutics, Deborah also demonstrated expertise in high throughput biochemistry at Millennium Pharmaceuticals and receptor pharmacology at LeukoSite. Deborah holds a Bachelor of Science degree in Microbiology from the University of Massachusetts Amherst.